Search research articles
Contact Us
Filters
Showing results (31-40 of 119) with videos related to
Page
of 12
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
June 5, 2013
A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial
Franck Morschhauser, Olivier Fitoussi, Corinne Haioun, et al.
Blood
|
October 28, 2010
The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy
Andy K Hsu, Hang Quach, Tsin Tai, et al.
Lancet (London, England)
|
July 20, 2020
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
Meletios Dimopoulos, Hang Quach, Maria-Victoria Mateos, et al.
Leukemia & Lymphoma
|
September 28, 2020
Excellent outcomes in older patients with primary CNS lymphoma treated with R-MPV/cytarabine without whole brain radiotherapy or autologous stem cell transplantation therapy
Maciej Tatarczuch, Erin Paul, Michael Gilberston, et al.
Expert Review of Hematology
|
October 13, 2025
Updated guidelines in the treatment of myeloma bone disease in 2025: consensus statement by the Medical and Scientific Advisory Group of Australia (MSAG) to Myeloma Australia
Angelina Yong, Kate Vandyke, Bradley Augustson, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 15, 2025
New Zealand Multiple Myeloma Patients Demonstrate Inferior Outcomes When Compared to Australian Counterparts - A Retrospective Cohort Study from the Myeloma and Related Diseases Registry (MRDR)
Jian Li, Yayehirad Melsew, Cameron Wellard, et al.
Frontiers in Oncology
|
February 5, 2025
Management of CAR-T cell therapy in patients with multiple myeloma: a systematic review and expert consensus in Australia
P Joy Ho, Hang Quach, M Hasib Sidiqi, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 30, 2025
Real-World Use of carfilzomib-lenalidomide-dexamethasone (KRd) and carfilzomib-dexamethasone (Kd) in Relapsed/Refractory Multiple Myeloma in the Asia Pacific Region: A Prospective Multicenter Observational Study
Hang Quach, Kihyun Kim, Raymond Siu Ming Wong, et al.
British Journal of Haematology
|
July 5, 2024
The impact of biomarkers of malignancy (IMWG SLiM criteria) in myeloma in a real-world population: Clinical characteristics, therapy and outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (ANZ MRDR)
P Joy Ho, Elizabeth Moore, Cameron Wellard, et al.
Internal Medicine Journal
|
November 28, 2022
Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group
Dipti Talaulikar, Douglas Joshua, Phoebe Joy Ho, et al.
Page
of 12
Search research articles
Search
Showing results (31-40 of 119) with videos related to
Sort By:
Page
of 12
European Journal of Cancer (Oxford, England : 1990)
|
June 5, 2013
A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial
Franck Morschhauser, Olivier Fitoussi, Corinne Haioun, et al.
Blood
|
October 28, 2010
The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy
Andy K Hsu, Hang Quach, Tsin Tai, et al.
Lancet (London, England)
|
July 20, 2020
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
Meletios Dimopoulos, Hang Quach, Maria-Victoria Mateos, et al.
Leukemia & Lymphoma
|
September 28, 2020
Excellent outcomes in older patients with primary CNS lymphoma treated with R-MPV/cytarabine without whole brain radiotherapy or autologous stem cell transplantation therapy
Maciej Tatarczuch, Erin Paul, Michael Gilberston, et al.
Expert Review of Hematology
|
October 13, 2025
Updated guidelines in the treatment of myeloma bone disease in 2025: consensus statement by the Medical and Scientific Advisory Group of Australia (MSAG) to Myeloma Australia
Angelina Yong, Kate Vandyke, Bradley Augustson, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 15, 2025
New Zealand Multiple Myeloma Patients Demonstrate Inferior Outcomes When Compared to Australian Counterparts - A Retrospective Cohort Study from the Myeloma and Related Diseases Registry (MRDR)
Jian Li, Yayehirad Melsew, Cameron Wellard, et al.
Frontiers in Oncology
|
February 5, 2025
Management of CAR-T cell therapy in patients with multiple myeloma: a systematic review and expert consensus in Australia
P Joy Ho, Hang Quach, M Hasib Sidiqi, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 30, 2025
Real-World Use of carfilzomib-lenalidomide-dexamethasone (KRd) and carfilzomib-dexamethasone (Kd) in Relapsed/Refractory Multiple Myeloma in the Asia Pacific Region: A Prospective Multicenter Observational Study
Hang Quach, Kihyun Kim, Raymond Siu Ming Wong, et al.
British Journal of Haematology
|
July 5, 2024
The impact of biomarkers of malignancy (IMWG SLiM criteria) in myeloma in a real-world population: Clinical characteristics, therapy and outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (ANZ MRDR)
P Joy Ho, Elizabeth Moore, Cameron Wellard, et al.
Internal Medicine Journal
|
November 28, 2022
Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group
Dipti Talaulikar, Douglas Joshua, Phoebe Joy Ho, et al.
Page
of 12